Engineering Next-Generation Therapeutics at Computational Scale.
India's premier AI-native Contract Research Organization. We engineer predictive deep learning architectures - DiscoveraAI, ReviveAI, and Enformis - to compress preclinical discovery, target validation, and solid-state formulation from years to under 72 hours.
Accelerated by global compute providers, premier state bio-incubators, and translational academic grants.
Three Synergistic Deeptech Pillars
From target to approved drug product: Ultraceuticals links de novo generative chemistry, knowledge-graph repurposing, and deep-learning solid-state formulation under Zero Trust Architecture.
DiscoveraAI™
De Novo Preclinical Discovery (DTPred, DockAI, AlphaFold/OmegaFold)
An integrated discovery environment that unifies structural, relational, and literature signals. From target identification with DTPred to high-confidence 3D protein structures via AlphaFold 2/OmegaFold and flexible molecular docking with DockAI.
Live Computational Platforms & Real Dashboards
Not conceptual mockups. Direct screenshots from our operational deeptech interfaces actively deployed for de novo molecular design, interactome drug repurposing, and autonomous regulatory intelligence.
DiscoveraAI™ Deeptech Suite
The flagship DiscoveraAI operational workbench directly captures real-time 3D PDB protein coordinates, computes Gibbs free energy (ΔG) via AutoDock Vina & DockAI, predicts ADMET pharmacokinetics, and optimizes pocket-conditioned ligands with zero false-positive filtering.
DiscoveraAI™ Deeptech Suite
High-Throughput De Novo Target Prediction, 3D Macromolecular Modeling & DockAI
ReviveAI™ (SCALEX) Engine
1.8 Million Nodes, 42M Biological Edges, Contrastive GNN Repurposing
Dossier360™ Intelligence Studio
Autonomous Hatch-Waxman Patent Swarms & BCS Bioequivalence Invalidation
Real-Time Structural & Docking Dynamics
Moving beyond static crystallographic models. Our engines simulate induced-fit protein cavity flexibility, conformational search trajectories, and nucleic acid interactions in 60fps real-time.
Atomic Forcefield Precision
Explicit solvent amber forcefield combined with QM/MM induced-fit sampling resolves allosteric binding grooves and calculates thermodynamic free energy (ΔG) with experimental-grade precision (±0.8 kcal/mol).
The End-to-End Discovery Architecture
From molecular data ingestion to clinical formulation insights. An integrated pipeline unifying Graph Neural Networks, Large Language Models, AlphaFold 2, and Zero Trust Architecture.
Zero Trust Data Ingestion
All biological, genomic, proteomic, and clinical datasets are securely ingested under Zero Trust Architecture. Cryptographic access verification, role-based isolation (RBAC), and immutable audit logs guarantee full data provenance and regulatory compliance.
Active Combinatorial Pipelines
Neurodegenerative Disease Combinatorial Project
Targeting Alzheimer's, Parkinson's & ALS CHIT1 microglial repolarization.
Novel Sleep Disorder Combinatorial Formulations
Personalized circadian regulation and dual receptor modulation.
Targeted Breast Health Therapeutics & Delivery
Targeted kinase crosstalk suppression with high tissue specificity.
BioFilm Omni™ 6.0 Bacterial Disrupter
EPS matrix disruption overcoming multi-drug antimicrobial resistance.
Test-Drive the Research Engine
Execute real-time simulated neural inferences across our active therapeutic and regulatory pipelines.
Assay 01: Phenotypic Microglial Repolarization (CHIT1 Target)
Four Years of Scientific Maturation
From founding algorithms to full-stack pharmaceutical intelligence. Fortem Biosciences has systematically de-risked every phase of the drug discovery, repurposing, and formulation lifecycle.
Incorporation & 1.8M-Node Interactome Knowledge Graph
Fortem Biosciences Pvt. Ltd. was legally incorporated in Bengaluru in June 2022, co-founding ULTRACEUTICALS with an algorithmic mandate. Initiated the construction of the human interactome heterogeneous knowledge graph (1.8M nodes, 42M biological edges) for deeptech computational biology.
DiscoveraAI Discovery Engine & Peer-Reviewed Research
Launched DiscoveraAI generative chemistry and DynaDock microsecond molecular dynamics suite. Published peer-reviewed research in Nutrients (Aug 2023, 15(17):3751) on oat avenanthramides and PI3K signaling in neurodegeneration with international university collaborators.
ReviveAI (SCALEX) Repurposing & Second Peer-Reviewed Paper
Deployed ReviveAI (SCALEX) enterprise drug repurposing using node-level contrastive GNNs with modality dropout defense. Published peer-reviewed research in Life (Apr 2024, 14(4):504) validating tangeretin for neuroinflammation-mediated neurodegeneration with JSS AHER & Sejong University.
Dossier360 Regulatory Swarms & Razorpay National Spotlight
Engineered Dossier360 multi-agent regulatory due-diligence intelligence for Orange/Purple book patent thicket triaging and bioequivalence risk automation. Featured nationally in Razorpay Rize's 'Backing India's Boldest' spotlight.
Enformis CMC AI, Razorpay Next Big Thing & AI CRO Repositioning
Launched Enformis predictive solid-state formulation AI (Tonset ±3.8°C across 106 validated APIs). Featured in Razorpay's 'Next Big Thing' Sketchpad episode and Bengaluru billboard. Formally repositioned as an AI-first CRO services model with proprietary computational software kept internal.
The UASPIRE Alliance Program
Partnering with universities, research institutions, and student fellows (Woxsen University, NIT Calicut, SKB Bio-incubator) to advance cutting-edge AI drug discovery and computational biology.
Accelerate Your Preclinical Discovery Program.
Whether you require de novo candidate generation, knowledge-graph drug repurposing, or preemptive formulation modeling - Fortem Biosciences delivers verified computational results.